Company Website

Contact Information:

Kristina Weber
Cell: 480-356-3762
kristina.weber@pfizer.com

 

Virtual Exhibit Hall Home

At Pfizer Rare Disease, we focus on smaller patient populations, but aspire for big impact. We strive to fundamentally transform what it means to live with a rare disease.

VYNDAMAX® (tafamidis) is the first and only, once-daily, single-capsule treatment for both the wild-type and hereditary forms of transthyretin amyloid cardiomyopathy (ATTR-CM), a rare and serious condition.

Indication
VYNDAMAX is a prescription medicine used to treat adults with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) to reduce death and hospitalization related to heart problems.

VYNDAMAX Labeling